DUBLIN, Feb. 19, 2020 /PRNewswire/ -- The "Anti-hypertension - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Anti-hypertension Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Anti-hypertension market.

A detailed picture of the Anti-hypertension pipeline landscape is provided, which includes the disease overview and Anti-hypertension treatment guidelines. The assessment part of the report embraces in-depth Anti-hypertension commercial assessment and clinical assessment of the Anti-hypertension pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-hypertension collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Anti-hypertension with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Anti-hypertension treatment.
• Anti-hypertension key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Anti-hypertension market.

Scope of the Report

• The Anti-hypertension report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Anti-hypertension across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Anti-hypertension therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
• Detailed Anti-hypertension research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Anti-hypertension.

Key Questions

• What are the current options for Anti-hypertension treatment?
• How many companies are developing therapies for the treatment of Anti-hypertension?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of Anti-hypertension?
• How many Anti-hypertension emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Anti-hypertension?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Anti-hypertension market?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Anti-hypertension?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Anti-hypertension therapies?
• What are the clinical studies going on for Anti-hypertension and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for Anti-hypertension?
• How many patents are granted and pending for the emerging therapies for the treatment of Anti-hypertension?

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/e1g4zm

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com